Endocrine Abstracts

Background: Metformin is currently the first drug of choice for treatment of type 2 diabetes (T2D). Metformin is known to reduce lipid levels through activation of AMP activated protein kinase-alpha (AMPKα). Metformin induces deficiency of vitamin B12 (B12) in patients with T2D. In humans, studies have shown that low B12 is associated with dyslipidemia (higher triglycerides and low HDL). Therefore, we investigated whether B12 deficiency m...

Background: Metformin is currently the first drug of choice for treatment of type 2 diabetes (T2D). Metformin is known to reduce lipid levels through activation of AMP activated protein kinase-alpha (AMPKα). Metformin induces deficiency of vitamin B12 (B12) in patients with T2D. In humans, studies have shown that low B12 is associated with dyslipidemia (higher triglycerides and low HDL). Therefore, we investigated whether B12 deficiency m...

Background: Vitamin B12 (B12) deficiency is associated with obesity and was recently shown to trigger lipid accumulation in the adipose tissues and liver. The body is capable of synthesizing fatty acids (FAs) endogenously via de novo lipogenesis in the liver. However, dysregulated levels are associated with adverse consequences in subjects. We therefore assessed B12 regulation of de novo fatty acid synthesis and the profile of various FAs in hepatocytes.<...

Background: The liver stores 10 μg cobalamin per gram protein and able to hold 50% (1–1.5 mg) of body’s B12. Making up the bulk of the liver, hepatocytes express receptors regulating cellular uptake of B12 in the liver. However, relationship between circulating and intracellular B12 levels as well as regulation of hepatic uptake of B12 is unexplored.Objective: To assess the regulation of cellular uptake and storage of B12 in hepatocytes in...

Background: Metformin is utilized in clinical trials for treatment of non-alcoholic fatty liver disease (NAFLD) and obesity. Metformin increases AMP:ATP ratio activating AMP activated protein kinase-alpha (AMPKα), a mediator of fatty acid oxidation (FAO) in the liver. Meanwhile, prolonged oral metformin therapy in T2DM decreases vitamin B12(B12) in patients and evidence shows that low B12 dysregulates lipid levels. We therefore investigated whether low B12 impairs FAO ind...

Background: Vitamin B12 (B12) deficiency results in disturbance of 1-carbon metabolites [methylmalonyl coenzyme A (MMA), homocysteine and S-adenosyl homocysteine (SAH), S-adenosyl methionine (SAM) and methionine] that collectively affect lipogenesis leading to risk of cardiovascular diseases. In clinical studies, B12 deficiency is associated with higher BMI and dyslipidaemia (high triglycerides and low HDL). The role of B12 in hepatic metabolism of...

Background: Vitamin B12 (B12) deficiency results in disturbance of 1-carbon metabolites [methylmalonyl coenzyme A (MMA), homocysteine and S-adenosyl homocysteine (SAH), S-adenosyl methionine (SAM) and methionine] that collectively affect lipogenesis leading to risk of cardiovascular diseases. In clinical studies, B12 deficiency is associated with higher BMI and dyslipidaemia (high triglycerides and low HDL). The role of B12 in hepatic metabolism of...

Background: The acquisition of brown-adipocyte-properties by white-adipocytes (BRITE-adipocytes) is an appealing-prospect to combat obesity and type-2-diabetes-Mellitus (T2DM). This may support counteracting the impact of inflammation and mitochondrial-dysfunction, which contribute to the obesity-pathogenesis. However, our previous-finding shave shown that the gut-derived-inflammatory-agent endotoxin can increase the inflammatory-response in white-adipose-tissue impacted by ob...